Pds biotech announces plan to initiate phase 3 study evaluating pds0101 in combination with keytruda® in head and neck cancer in 2023

Company has completed phase 3 manufacturing of pds0101 for randomized, controlled, registrational trial in recurrent/metastatic hpv16-positive head and neck cancer company has completed phase 3 manufacturing of pds0101 for randomized, controlled, registrational trial in recurrent/metastatic hpv16-positive head and neck cancer
PDSB Ratings Summary
PDSB Quant Ranking